9.18
0.88%
+0.08
Precedente Chiudi:
$9.10
Aprire:
$9.08
Volume 24 ore:
365.64K
Capitalizzazione di mercato:
$537.25M
Reddito:
-
Utile/perdita netta:
$-201.59M
Rapporto P/E:
-2.0959
EPS:
-4.38
Flusso di cassa netto:
$-139.21M
1 W Prestazione:
+2.34%
1M Prestazione:
-12.57%
6M Prestazione:
+7.75%
1 anno Prestazione:
-10.09%
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
877 742 8466
Indirizzo
100 Campus Drive, Suite 102, Florham Park, NJ
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-08-09 | Iniziato | H.C. Wainwright | Buy |
2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
2023-03-13 | Iniziato | Craig Hallum | Buy |
2022-10-21 | Iniziato | Jefferies | Buy |
2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
2021-02-02 | Iniziato | Guggenheim | Buy |
2020-06-26 | Downgrade | Goldman | Neutral → Sell |
2019-11-20 | Iniziato | Evercore ISI | Outperform |
2019-11-19 | Iniziato | Goldman | Neutral |
2019-11-19 | Iniziato | Jefferies | Buy |
2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
GlobeNewswire Inc.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
GlobeNewswire Inc.
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Benzinga
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GlobeNewswire Inc.
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Phathom Pharmaceuticals Inc (PHAT) Reddito netto 2024
PHAT l'utile netto (TTM) è stato di -$201.59 milioni per il trimestre terminato il 2023-12-31, un -1.96% diminuire anno su anno.
Phathom Pharmaceuticals Inc (PHAT) Flusso di cassa 2024
PHAT ha registrato un flusso di cassa disponibile (TTM) di -$139.21 milioni per il trimestre conclusosi con 2023-12-31, un +5.66% aumento anno su anno.
Phathom Pharmaceuticals Inc (PHAT) Utile per azione 2024
L'utile per azione (TTM) di PHAT è stato pari a -$3.94 per il trimestre terminato il 2023-12-31, un +21.98% crescita anno su anno.
Phathom Pharmaceuticals Inc Azioni (PHAT) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Curran Terrie | President and Chief Executive |
Mar 22 '24 |
Sale |
9.11 |
16,851 |
153,513 |
410,784 |
TAKEDA PHARMACEUTICAL CO LTD | 10% Owner |
Jan 24 '24 |
Sale |
8.10 |
3,703,703 |
29,999,994 |
3,755,583 |
Henderson Molly | CFO and CBO |
Jan 19 '24 |
Sale |
7.75 |
6,307 |
48,900 |
98,698 |
Henderson Molly | CFO and CBO |
Nov 20 '23 |
Sale |
7.24 |
2,127 |
15,403 |
103,061 |
Parikh Asit | Director |
Nov 08 '23 |
Buy |
7.80 |
2,500 |
19,500 |
55,000 |
Parikh Asit | Director |
Nov 07 '23 |
Buy |
7.76 |
4,000 |
31,040 |
52,500 |
Parikh Asit | Director |
Nov 06 '23 |
Buy |
8.04 |
1,000 |
8,040 |
48,500 |
Henderson Molly | CFO and CBO |
Nov 01 '23 |
Sale |
8.88 |
12,492 |
110,871 |
105,188 |
Henderson Molly | CFO and CBO |
Jun 02 '23 |
Sale |
11.41 |
1,960 |
22,368 |
68,506 |
Henderson Molly | CFO and CBO |
May 22 '23 |
Sale |
12.87 |
2,110 |
27,165 |
70,466 |
Capitalizzazione:
|
Volume (24 ore):